Intellia Addresses CRISPR Trial's Germline Transmission Concerns
Intellia Therapeutics sought to address concerns about accidental germline transmission in CRISPR trials by sharing detailed information about studies conducted to assess the risks. The company stated that there is no evidence of vertical germline transmission of renegade CRISPR components. Intellia is a leading company in the field of in vivo gene editing therapies and has previously demonstrated the successful alteration of DNA in human cells to treat disease. However, during toxicology studies in non-human primates, editing was found to have occurred at low levels in organs other than the liver, including the spleen, adrenal glands, and ovaries of female monkeys.